Mediators of ocular angiogenesis

Journal of Genetics

Volumn 88, Issue 4, 2009, Pages 495-515

  Qazi, Yureeda ^a   Maddula, Surekha ^a   Ambati, Balamurali K ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Age related macular degeneration; Angiopoietin; Complement; Corneal neovascularization; Diabetic retinopathy; Endostatin; Erythropoietin; Flk 1; Flt 1; Gene therapy; Inflammation; Ocular angiogenesis; PEDF; Retinal neovascularization; Retinopathy of prematurity; Robo4; Tie2; TLR 3; VEGF

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; MATRIX METALLOPROTEINASE; VASCULOTROPIN A;

ANIMAL; CORNEA NEOVASCULARIZATION; EYE; GENETIC POLYMORPHISM; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; REVIEW; VASCULARIZATION;

ANIMALS; CORNEAL NEOVASCULARIZATION; EYE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MATRIX METALLOPROTEINASES; POLYMORPHISM, GENETIC; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77951932130     PISSN: 00221333     EISSN: 09737731     Source Type: Journal    
DOI: 10.1007/s12041-009-0068-0     Document Type: Review

References (285)

1. Abdiu O. and van Setten G. 2008 Antiangiogenic activity in tears: presence of pigment-epithelium-derived factor. New insights and preliminary results. Ophthalmic Res. 40, 16-18.
2. Adamis A. P. and Berman A. J. 2008 Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin. Immunopathol. 30, 65-84.
3. Adamis A. P., Miller J. W., Bernal M. T., D'Amico D. J., Folkman J., Yeo T. K. et al. 1994 Increased vascular endothelial growth factor levels in the vitreous of eyes with diabetic retinopathy. Am. J. Ophthalmol. 118, 445-450.
4. Alon T., Hemo I., Itin A., Pe'er J., Stone J. and E. Keshet 1995 Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1, 1024-1028.
5. Ambati B. K., Joussen A. M., Ambati J., Moromizato Y., Guha C., Javaherian K. et al. 2002 Angiostatin inhibits and regresses corneal neovascularization. Arch. Ophthalmol. 120, 1063-1068.
6. Ambati B. K., Anand A., Joussen A. M., Kuziel W. A., Adamis A. P. and Ambati J. 2003a Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest. Ophthalmol. Vis. Sci. 44, 590-593.
7. Ambati B. K., Joussen A. M., Kuziel W. A., Adamis A. P. and Ambati J. 2003b Inhibition of corneal neovascularization by genetic ablation of CCR2. Cornea22, 465-467.
8. Ambati J., Anand A., Fernandez S., Sakurai E., Lynn B. C., Kuziel W. A. et al. 2003c An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2- deficient mice. Nat. Med. 9, 1390-1397.
9. Ambati B. K., Nozaki M., Singh N., Takeda A., Jani P. D., Suthar T. et al. 2006 Corneal avascularity is due to soluble VEGF receptor-1. Nature443, 993-997.
10. Amin R., Puklin J. E. and Frank R. N. 1994 Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 35, 3178-3188.
11. Anand-Apte B., Pepper M. S., Voest E., Montesano R., Olsen B., Murphy G. et al. 1997 Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest. Ophthalmol. Vis. Sci. 38, 817-823.
12. Ando A., Yang A., Nambu H. and Campochiaro P. A. 2002 Blockade of nitric-oxide synthase reduces choroidal neovascularization. Mol. Pharmacol. 62, 539-544.
13. Apte S. S., Mattei M. G. and Olsen B. R. 1994 Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics19, 86-90.
14. Apte R. S., Barreiro R. A., Duh E., Volpert O. and Ferguson T. A. 2004 Stimulation of neovascularization by the anti-angiogenic factor PEDF. Invest. Ophthalmol. Vis. Sci. 45, 4491-4497.
15. Arden G. B., Sidman R. L., Arap W. and Schlingemann R. O. 2005 Spare the rod and spoil the eye. Br. J. Ophthalmol. 89, 764-769.
16. Arjamaa O. and Nikinmaa M. 2006 Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp. Eye Res. 83, 473-483.
17. Ashton N., Ward B. and Serpell G. 1954 Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br. J. Ophthalmol. 38, 397-432.
18. Azar D. T. 2006 Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans. Am. Ophthalmol. Soc. 104, 264-302.
19. Azar D. T., Hahn T. W., Jain S., Yeh Y. C. and Stetler-Stevensen W. G. 1996 Matrix metalloproteinases are expressed during wound healing after excimer laser keratectomy. Cornea15, 18-24.
20. Becerra S. P. and Amaral J. 2002 Erythropoietin - an endogenous retinal survival factor. N. Engl. J. Med. 347, 1968-1970.
21. Beck Jr L. and D'Amore P. A. 1997 Vascular development: cellular and molecular regulation. FASEB J. 11, 365-373.
22. Beranek M., Kolar P., Tschoplova S., Kankova K. and Vasku A. 2008 Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy. Mol. Vis. 14, 1114-1121.
23. Berglin L., Sarman S., van der Ploeg I., Steen B., Ming Y., Itohara S. et al. 2003 Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2- deficient mice. Invest. Ophthalmol. Vis. Sci. 44, 403-408.
24. Bhutto I. A., McLeod D. S., Hasegawa T., Kim S. Y., Merges C., Tong P. et al. 2006 Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp. Eye Res. 82, 99-110.
25. Bikfalvi A. and Han Z. C. 1994 Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia8, 523-529.
26. Blaauwgeers H. G., Holtkamp G. M., Rutten H., Witmer A. N., Koolwijk P., Partanen T. K. et al. 1999 Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am. J. Pathol. 155, 421-428.
27. Boehm B., Lang G., Feldmann B., Kurkhaus A., Rosinger S., Volpert O. et al. 2003 Proliferative diabetic retinopathy is associated with a low level of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor. a pilot study. Horm. Metab. Res. 35, 382-386.
28. Bojanowski C. M., Shen D., Chew E. Y., Ning B., Csaky K. G., Green W. R. et al. 2006 An apolipoprotein E variant may protect against age-related macular degeneration through cytokine regulation. Environ. Mol. Mutagen. 47, 594-602.
29. Bora N. S., Kaliappan S., Jha P., Xu Q., Sohn J. H., Dhaulakhandi D. B. et al. 2006 Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H. J. Immunol. 177, 1872-1878.
30. Bora N. S., Kaliappan S., Jha P., Xu Q., Sivasankar B., Harris C. L. et al. 2007 CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration. J. Immunol. 178, 1783-1790.
31. Bora N. S., Jha P. and Bora P. S. 2008 The role of complement in ocular pathology. Semin. Immunopathol. 30, 85-95.
32. Brown M. S., Baron A. E., France E. K. and Hamman R. F. 2006 Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity. J. AAPOS10, 143-149.
33. Browning A. C., Dua H. S. and Amoaku W. M. 2008 The effects of growth factors on the proliferation and in vitro angiogenesis of human macular inner choroidal endothelial cells. Br. J. Ophthalmol. 92, 1003-1008.
34. Buraczynska M., Ksiazek P., Baranowicz-Gaszczyk I. and Jozwiak L. 2007 Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. Nephrol. Dial. Transplant. 22, 827-832.
35. Burger P. C., Chandler D. B. and Klintworth G. K. 1983 Corneal neovascularization as studied by scanning electron microscopy of vascular casts. Lab. Invest. 48, 169-180.
36. Burger P. C., Chandler D. B. and Klintworth G. K. 1985 Experimental corneal neovascularization: biomicroscopic, angiographic, and morphologic correlation. Cornea4, 35-41.
37. Campochiaro P. A. 2004 Ocular neovascularisation and excessive vascular permeability. Expert Opin. Biol. Ther. 4, 1395-1402.
38. Campochiaro P. A. 2006 Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther. 13, 559-562.
39. Cao R., Wu H. L., Veitonmaki N., Linden P., Farnebo J., Shi G. Y. et al. 1999 Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc. Natl. Acad. Sci. USA96, 5728-5733.
40. Carmeliet P. 2003 Angiogenesis in health and disease. Nat. Med. 9, 653-660.
41. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M. et al. 1996 Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature380, 435-439.
42. Chan C. C., Shen D., Zhou M., Ross R. J., Ding X., Zhang K. et al. 2007 Human HtrA1 in the archived eyes with age-related macular degeneration. Trans. Am. Ophthalmol. Soc. 105, 92-97; discussion 97-98.
43. Chang J. H., Gabison E. E., Kato T. and Azar D. T. 2001 Corneal neovascularization. Curr. Opin. Ophthalmol. 12, 242-249.
44. Chan-Ling T., Gock B. and Stone J. 1995 The effect of oxygen on vasoformative cell division. Evidence that 'physiological hypoxia' is the stimulus for normal retinal vasculogenesis. Invest. Ophthalmol. Vis. Sci. 36, 1201-1214.
45. Chen J. and Smith L. E. 2007 Retinopathy of prematurity. Angiogenesis10, 133-140.
46. Chen J., Hicks D., Brantley-Sieders D., Cheng N., McCollum G. W., Qiwerdich X. et al. 2006 Inhibition of retinal neovascularization by soluble EphA2 receptor. Exp. Eye. Res. 82, 664-673.
47. Chen J., Connor K. M., Aderman C. M. and Smith L. E. 2008 Erythropoietin deficiency decreases vascular stability in mice. J. Clin. Invest. 118, 526-533.
48. Chen J., Connor K. M., Aderman C. M., Willett K. L., Aspegren O. P. and Smith L. E. 2009 Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest. Ophthalmol. Vis. Sci. 50, 1329-1335.
49. Cheung A. K., Fung M. K., Lo A. C., Lam T. T., So K. F., Chung S. S. et al. 2005 Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes54, 3119-3125.
50. Chmielewska K., Robaszkiewicz J. and Kosatka M. 2008 Role of the retinal pigment epithelium (RPE) in the pathogenesis and treatment of diabetic macular edema (DME). Klin. Oczna110, 318-320.
51. Churchill A. J., Carter J. G., Ramsden C., Turner S. J., Yeung A., Brenchley P. E. et al. 2008 VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 49, 3611-3616.
52. Cohen M. P., Hud E., Shea E. and Shearman C. W. 2008 Vitreous fluid of db/db mice exhibits alterations in angiogenic and metabolic factors consistent with early diabetic retinopathy. Ophthalmic Res. 40, 5-9.
53. Combadiere C., Feumi C., Raoul W., Keller N., Rodero M., Pezard A. et al. 2007 CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J. Clin. Invest. 117, 2920-2928.
54. Conley Y. P., Jakobsdottir J., Mah T., Weeks D. E., Klein R., Kuller L. et al. 2006 CFH, ELOVL4, PLEKHA1 and LOC387715 genes and susceptibility to age-related maculopathy: AREDS and CHS cohorts and meta-analyses. Hum. Mol. Genet. 15, 3206-3218.
55. Connor K. M., SanGiovanni J. P., Lofqvist C., Aderman C. M., Chen J., Higuchi A. et al. 2007 Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med. 13, 868-873.
56. Crawford T. N., Alfaro D. V. 3rd, Kerrison J. B. and Jablon E. P. 2009 Diabetic retinopathy and angiogenesis. Curr. Diabetes Rev. 5, 8-13.
57. Cross M. J. and Claesson-Welsh L. 2001 FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22, 201-207.
58. Cursiefen C., Kuchle M. and Naumann G. O. 1998 Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea17, 611-613.
59. Dawson D. W., Volpert O. V., Gillis P., Crawford S. E., Xu H., Benedict W. et al. 1999 Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science285, 245-248.
60. Demircan N., Safran B. G., Soylu M., Ozcan A. A. and Sizmaz S. 2006 Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye20, 1366-1369.
61. Despriet D. D., van Duijn C. M., Oostra B. A., Uitterlinden A. G., Hofman A., Wright F. et al. 2009 Complement component C3 and risk of age-related macular degeneration. Ophthalmology116, 474-480; e472.
62. Economopoulou M., Bdeir K., Cines D. B., Fogt F., Bdeir Y., Lubkowski J. et al. 2005 Inhibition of pathologic retinal neovascularization by alpha-defensins. Blood106, 3831-3838.
63. Edwards A. O., Chen D., Fridley B. L., James K. M., Wu Y., Abecasis G. et al. 2008 Toll-like receptor polymorphisms and age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 49, 1652-1659.
64. Fang I. M., Yang C. H., Yang C. M. and Chen M. S. 2009 Comparative effects of fatty acids on proinflammatory gene cyclooxygenase 2 and inducible nitric oxide synthase expression in retinal pigment epithelial cells. Mol. Nutr. Food Res. 53, 739-750.
65. Ferreras M., Felbor U., Lenhard T., Olsen B. R. and Delaisse J. 2000 Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 486, 247-251.
66. Folkman J. 1971 Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186.
67. Folkman J. 1995 Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31.
68. Friedlander M., Brooks P. C., Shaffer R. W., Kincaid C. M., Varner J. A. and Cheresh A. 1995 Definition of two angiogenic pathways by distinct alpha v integrins. Science270, 1500-1502.
69. Friedlander M., Theesfeld C. L., Sugita M., Fruttiger M., Thomas M. A., Chang S. and Cheresh D. A. 1996 Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA93, 9764-9769.
70. Fukumura D., Gohongi T., Kadambi A., Izumi Y., Ang J., Yun C. O. et al. 2001 Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl. Acad. Sci. USA98, 2604-2609.
71. Funatsu H., Yamashita H., Noma H., Mimura T., Nakamura S., Sakata K. et al. 2005 Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes. Arch. Clin. Exp. Ophthalmol. 243, 3-8.
72. Gao G., Li Y., Zhang D., Gee S., Crosson C. and Ma J. 2001 Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett. 489, 270-276.
73. Gerritsen M. E., Soriano R., Yang S., Zlot C., Ingle G., Toy K. et al. 2003 Branching out: a molecular fingerprint of endothelial differentiation into tube-like structures generated by Affymetrix oligonucleotide arrays. Microcirculation10, 63-81.
74. Gold B., Merriam J. E., Zernant J., Hancox L. S., Taiber A. J., Gehrs K. et al. 2006 Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat. Genet. 38, 458-462.
75. Grant M. B., Afzal A., Spoerri P., Pan H., Shaw L. C. and Mames R. N. 2004 The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin. Investig. Drugs13, 1275-1293.
76. Grossniklaus H. E., Ling J. X., Wallace T. M., Dithmar S., Lawson D. H., Cohen C. et al. 2002 Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol. Vis. 8, 119-126.
77. Guo L., Hussain A. A., Limb G. A. and Marshall J. 1999 Agedependent variation in metalloproteinase activity of isolated human Bruch's membrane and choroid. Invest. Ophthalmol. Vis. Sci. 40, 2676-2682.
78. Gupta N., Brown K. E. and Milam A. H. 2003 Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration. Exp. Eye Res. 76, 463-471.
79. Hanahan D. and Folkman J. 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell86, 353-364.
80. Hangai M., Moon Y. S., Kitaya N., Chan C. K., Wu D. Y., Peters K. G. et al. 2001 Systemically expressed soluble Tie2 inhibits intraocular neovascularization. Hum. Gene. Ther. 12, 1311-1321.
81. Hattenbach L. O., Falk B., Nurnberger F., Koch F. H. and Ohrloff C. 2002 Detection of inducible nitric oxide synthase and vascular endothelial growth factor in choroidal neovascular membranes. Ophthalmologica216, 209-214.
82. Hellstrom A., Perruzzi C., Ju M., Engstrom E., Hard A. L., Liu J. L. et al. 2001 Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc. Natl. Acad. Sci. USA98, 5804-5808.
83. Hellstrom A., Engstrom E., Hard A. L., Albertsson-Wikland K., Carlsson B., Niklasson A. et al. 2003 Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics112, 1016-1020.
84. He T., Ai M., Zhao X. H. and Xing Y. Q. 2007 Inducible nitric oxide synthase mediates hypoxia-induced hypoxia-inducible factor-1 alpha activation and vascular endothelial growth factor expression in oxygen-induced retinopathy. Pathobiology74, 336-343.
85. Hiratsuka S., Kataoka Y., Nakao K., Nakamura K., Morikawa S., Tanaka S. et al. 2005 Vascular endothelial growth factor A (VEGF-A) is involved in guidance of VEGF receptor-positive cells to the anterior portion of early embryos. Mol. Cell Biol. 25, 355-363.
86. Hoffmann S., He S., Ehren M., Ryan S. J., Wiedemann P. and Tanaka S. et al. 2006 MMP-2 and MMP-9 secretion by rpe is stimulated by angiogenic molecules found in choroidal neovascular membranes. Retina26, 454-461.
87. Holekamp N. M., Bouck N. and Volpert O. 2002 Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am. J. Ophthalmol. 134, 220-227.
88. Honda S., Nagai T. and Negi A. 2009 Anti-angiogenic effects of non-peptide integrin alphavbeta3 specific antagonist on laserinduced choroidal neovascularization in mice. Graefes Arch. Clin. Exp. Ophthalmol. 247, 515-522.
89. Hughes S., Yang H. and Chan-Ling T. 2000 Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest. Ophthalmol. Vis. Sci. 41, 1217-1228.
90. Hughes J. M., Kuiper E. J., Klaassen I., Canning P., Stitt A. W., van Bezu J. et al. 2007 Advanced glycation and products casue increased CCN family and extracellular matrix gene expression in the diabetic rodent retina. Diabetologia50, 1089-1098.
91. Hutchings H., Maitre-Boube M., Tombran-Tink J. and Plouet J. 2002 Pigment epithelium-derived factor exerts opposite effects on endothelial cells of different phenotypes. Biochem. Biophys. Res. Commun. 294, 764-769.
92. Iizuka H., Awata T., Osaki M., Neda T., Kurihara S., Inoue K. et al. 2007 Promoter polymorphisms of the pigment epithelium-derived factor gene are associated with diabetic retinopathy. Biochem. Biophys. Res. Commun. 361, 421-426.
93. Iliaki E., Poulaki V., Mitsiades N., Mitsiades C. S., Miller J. W. and Gragoudas E. S. 2009 Role of {alpha}4 integrin (cd49d) in the pathogenesis of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 50, 4890-4904.
94. Ishida S. 2009 Lifestyle-related diseases and anti-aging ophthalmology: suppression of retinal and choroidal pathologies by inhibiting renin-angiotensin system and inflammation. Nippon Ganka Gakkai Zasshi113, 403-423.
95. Isner J. M. and Asahara T. 1999 Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J. Clin. Invest. 103, 1231-1236.
96. Itoh N. and Ornitz D. M. 2004 Evolution of the Fgf and Fgfr gene families. Trends Genet. 20, 563-569.
97. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H. and Itohara S. 1998 Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58, 1048-1051.
98. Jani P. D., Singh N., Jenkins C., Raghava S., Mo Y., Amin S. et al. 2007 Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest. Ophthalmol. Vis. Sci. 48, 2030-2036.
99. Jaquet K., Krause K., Tawakol-Khodai M., Geidel S. and Kuck K. H. 2002 Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc. Res. 64, 326-333.
100. Jiang J., Xia X. B., Xu H. Z., Xiong Y., Song W. T., Xiong S. Q. et al. 2009 Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF. J. Cell. Physiol. 218, 66-74.
101. Jones C. A., London N. R., Chen H., Park K. W., Sauvaget D., Stockton R. A. et al. 2008 Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat. Med. 14, 448-453.
102. Kadonosono K., Yazama F., Itoh N., Sawada H. and Ohno S. 1999 Expression of matrix metalloproteinase-7 in choroidal neovascular membranes in age-related macular degeneration. Am. J. Ophthalmol. 128, 382-384.
103. Kamei M. and Hollyfield J. G. 1999 TIMP-3 in Bruch's membrane: changes during aging and in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 40, 2367-2375.
104. Kaneko T., Fujii S., Matsumoto A., Goto D., Ishimori N., Watano K. et al. 2002 Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modulation by fibric acid. Arterioscler. Thromb. Vasc. Biol. 22, 855-860.
105. Karakousis P. C., John S. K., Behling K. C., Surace E. M., Smith J. E., Hendrickson A. et al. 2001 Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues. Mol. Vis. 7, 154-163.
106. Keck P. J., Hauser S. D., Krivi G., Sanzo K., Warren T., Feder J. et al. 1989 Vascular permeability factor, an endothelial cellmitogen related to PDGF. Science246, 1309-1312.
107. Kern T. S. 2007 Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp. Diabetes Res. 2007, 95103.
108. Kim I., Moon S. O., Park S. K., Chae S. W. and Koh G. Y. 2001 Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ. Res. 89, 477-479.
109. Kim J. H., Yu Y. S., Cho C. S. and Kim K. W. 2009 Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy. J. Cereb. Blood Flow Metab. 29, 621-628.
110. Kita T., Hata Y., Miura M., Kawahara S., Nakao S. and Ishibashi T. 2007 Functional characteristics of connective tissue growth factor on vitreoretinal cells. Diabetes56, 1421-1428.
111. Kitaoka T., Morse L. S., Schneeberger S., Ishigooka H. and Hjelmeland L. M. 1997 Expression of FGF5 in choroidal neovascular membranes associated with ARMD. Curr. Eye Res. 16, 396-399.
112. Klein R. J., Zeiss C., Chew E. Y., Tsai J. Y., Sackler R. S., Haynes C. et al. 2005 Complement factor H polymorphism in age-related macular degeneration. Science308, 385-389.
113. Klein S., Giancotti F. G., Presta M., Albelda S. M., Buck C. A. and Rifkin D. B. 1993 Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol. Biol. Cell4, 973-982.
114. Kleinman M. E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J. Z. et al. 2008 Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature452, 591-597.
115. Krantz S. B. 1991 Erythropoietin. Blood77, 419-434.
116. Kuiper E. J., van Nieuwenhoven F. A., de Smet M. D., van Meurs J. C., Tanck M. W., Oliver N. et al. 2008 The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One3, e2675.
117. Kvanta A. 2006 Ocular angiogenesis: the role of growth factors. Acta Ophthalmol. Scand84, 282-288.
118. Kvanta A., Shen W. Y., Sarman S., Seregard S., Steen B. and Rakoczy E. 2000 Matrix metalloproteinase (MMP) expression in experimental choroidal neovascularization. Curr. Eye Res. 21, 684-690.
119. Langford K., Nicolaides K. and Miell J. P. 1998 Maternal and fetal insulin-like growth factors and their binding proteins in the second and third trimesters of human pregnancy. Hum. Reprod. 13, 1389-1393.
120. Lee P., Wang C. C. and Adamis A. P. 1998 Ocular neovascularization: an epidemiologic review. Surv. Ophthalmol. 43, 245-269.
121. Lee P. C., Kibbe M. R., Schuchert M. J., Stolz D. B., Watkins S. C., Griffith B. P. et al. 2000 Nitric oxide induces angiogenesis and upregulates alpha(v)beta(3) integrin expression on endothelial cells. Microvasc. Res. 60, 269-280.
122. Leung D. W., Cachianes G., Kuang W. J., Goeddel D. V. and Ferrara N. 1989 Vascular endothelial growth factor is a secreted angiogenic mitogen. Science246, 1306-1309.
123. Lin H. C., Chang J. H., Jain S., Gabison E. E., Kure T., Kato T. et al. 2001 Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest. Ophthalmol. Vis. Sci. 42, 2517-2524.
124. Lin J. M., Wan L., Tsai Y. Y., Lin H. J., Tsai Y., Lee C. C. et al. 2008 Pigment epithelium-derived factor gene Met72Thr polymorphism is associated with increased risk of wet age-related macular degeneration. Am. J. Ophthalmol. 145, 716-721.
125. Lip P. L., Chatterjee S., Caine G. J., Hope-Ross M., Gibson J., Blann A. D. et al. 2004 Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor Tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Br. J. Ophthalmol. 88, 1543-1546.
126. Liu J., Lin T. H., Cole A. G., Wen R., Zhao L., Brescia M. R. et al. 2008 Identification and characterization of small-molecule inhibitors of Tie2 kinase. FEBS Lett. 582, 785-791.
127. Lommatzsch A., Hermans P., Muller K. D., Bornfeld N., Bird A. C. and Pauleikhoff D. 2008 Are low inflammatory reactions involved in exudative age-related macular degeneration? Morphological and immunhistochemical analysis of AMD associated with basal deposits. Graefes Arch. Clin. Exp. Ophthalmol. 246, 803-810.
128. Lu P. C., Ye H., Maeda M. and Azar D. T. 1999 Immunolocalization and gene expression of matrilysin during corneal wound healing. Invest. Ophthalmol. Vis. Sci. 40, 20-27.
129. Lukiw W. J. and N. G. Bazan 2008 Docosahexaenoic acid and the aging brain. J. Nutr. 138, 2510-2514.
130. Madan A. and Penn J. S. 2003 Animal models of oxygen-induced retinopathy. Front. Biosci. 8, 1030-1043.
131. Maeda M., Vanlandingham B. D., Ye H., Lu P. C. and Azar D. T. 1998 Immunoconfocal localization of gelatinase B expressed by migrating intrastromal epithelial cells after deep annular excimer keratectomy. Curr. Eye Res. 17, 836-843.
132. Mahabeleshwar G. H., Feng W., Phillips D. R. and Byzova T. V. 2006 Integrin signalling is critical for pathological angiogenesis. J. Exp. Med. 203, 2495-2507.
133. Malik R. A., Li C., Aziz W., Olson J. A., Vohra A., McHardy K. C. et al. 2005 Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy. J. Cell Mol. Med. 9, 692-697.
134. Matsunaga N., Chikaraishi Y., Izuta H., Ogata N., Shimazawa M., Matsumura M. et al. 2008 Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. Ophthalmology115, 1916-1922.
135. Matsushima M., Ogata N., Takada Y., Tobe T., Yamada H., Takahashi K. et al. 1996 FGF receptor 1 expression in experimental choroidal neovascularization. Jpn. J. Ophthalmol. 40, 329-338.
136. Mattila M. M., Ruohola J. K., Valve E. M., Tasanen M. J., Seppanen J. A. and Harkonen L. 2001 FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells. Oncogene20, 2791-2804.
137. McKay G. J., Silvestri G., Patterson C. C., Hogg R. E., Chakravarthy U. and A. E. Hughes 2009 Further assessment of the complement component 2 and factor B region associated with agerelated macular degeneration. Invest. Ophthalmol. Vis. Sci. 50, 533-539.
138. McLeod D. S., Taomoto M., Cao J., Zhu Z., Witte L. and Lutty G. A. 2002 Localization of VEGF receptor2 (KDR/Flk1) and effects of blocking it in oxygeninduced retinopathy. Invest. Ophthalmol. Vis. Sci. 43, 474-482.
139. Meleth A. D., Agron E., Chan C. C., Reed G. F., Arora K., Byrnes G. et al. 2005 Serum inflammatory markers in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 46, 4295-4301.
140. Mignatti P. and Rifkin D. B. 2000 Nonenzymatic interactions between proteinases and the cell surface: novel roles in normal and malignant cell physiology. Adv. Cancer Res. 78, 103-157.
141. Miyamoto K., Khosrof S., Bursell S. E., Moromizato Y., Aiello L. P., Ogura Y. et al. 2000 Vascular endothelial growth factor (VEGF)induced retinal vascular permeability is mediated by intercellular adhesion molecule1 (ICAM1). Am. J. Pathol. 156, 1733-1739.
142. Morello C. M. 2007 Etiology and natural history of diabetic retinopathy: an overview. Am. J. Health Syst. Pharm. 64, suppl. 12, S3-S7.
143. Mori K., Duh E., Gehlbach P., Ando A., Takahashi K., Pearlman J. et al. 2001 Pigment epitheliumderived factor inhibits retinal and choroidal neovascularization. J. Cell Physiol. 188, 253-263.
144. Mori K., Gehlbach P., Ando A., McVey D., Wei L. and Campochiaro P. A. 2002 Regression of ocular neovascularization in response to increased expression of pigment epitheliumderived factor. Invest. Ophthalmol. Vis. Sci. 43, 2428-2434.
145. Morita M., Ohneda O., Yamashita T., Takahashi S., Suzuki N., Nakajima O. et al. 2003 HLF/HIF2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 22, 1134-1146.
146. Moussad E. E. and Brigstock D. R. 2000 Connective tissue growth factor. What's in a name? Mol. Genet. Metab. 71, 276-292.
147. Mukherjee P. K., Chawla A., Loayza M. S. and Bazan N. G. 2007 Docosanoids are multifunctional regulators of neural cell integrity and fate: significance in aging and disease. Prostaglandins Leukot. Essent. Fatty Acids77, 233-238.
148. Mullins R. F., Russell S. R., Anderson D. H. and Hageman G. S. 2000 Drusen associated with aging and agerelated macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 14, 835-846.
149. Murata T., Nakagawa K., Khalil A., Ishibashi T., Inomata H. and Sueishi K. 1996 The temporal and spatial vascular endothelial growth factor expression in retinal vasculogenesis of rat neonates. Lab. Invest. 74, 68-77.
150. Murugeswari P., Shukla D., Rajendran A., Kim R., Namperumalsamy P. and Muthukkaruppan V. 2008 Proinflammatory cytokines and angiogenic and antiangiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease. Retina28, 817-824.
151. Naduk-Kik J. and Hrabec E. 2008 The role of matrix metalloproteinases in the pathogenesis of diabetes mellitus and progression of diabetes retinopathy. Postepy Hig. Med. Dosw. 62, 442-450.
152. Nagineni C. N., Samuel W., Nagineni S., Pardhasaradhi K., Wiggert B., Detrick B. et al. 2003 Transforming growth factorbeta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogenactivated protein kinases. J. Cell Physiol. 197, 453-462.
153. Nakai K., Fainaru O., Bazinet L., Pakneshan P., Benny O., Pravda E. et al. 2008 Dendritic cells augment choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 49, 3666-3670.
154. Nakamura S., Iwasaki N., Funatsu H., Kitano S. and Iwamoto Y. 2009 Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 247, 21-26.
155. Nambu H., Nambu R., Oshima Y., Hackett S. F., Okoye G., Wiegand S. et al. 2004 Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood retinal barrier. Gene Ther. 11, 865-873.
156. Nambu H., Umeda N., Kachi S., Oshima Y., Akiyama H., Nambu R. et al. 2005 Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization. J. Cell Physiol. 204, 227-235.
157. Nozaki M., Raisler B. J., Sakurai E., Sarma J. V., Barnum S. R., Lambris J. D. et al. 2006 Drusen complement components C3a and C5a promote choroidal neovascularization. Proc. Natl. Acad. Sci. USA103, 2328-2333.
158. Ogata N., Matsuoka M., Matsuyama K., Shima C., Tajika A., Nishiyama T. et al. 2007 Plasma concentration of pigment epitheliumderived factor in patients with diabetic retinopathy. J. Clin. Endocrinol. Metab. 92, 1176-1179.
159. Ogata N., Nishikawa M., Nishimura T., Mitsuma Y. and Matsumura M. 2002a Unbalanced vitreous levels of pigment epitheliumderived factor and vascular endothelial growth factor in diabetic retinopathy. Am. J. Ophthalmol. 134, 348-353.
160. Ogata N., Wada M., Otsuji T., Jo N., TombranTink J. and Matsumura M. 2002b Expression of pigment epitheliumderived factor in normal adult rat eye and experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 43, 1168-1175.
161. Ohlmann A. V., Ohlmann A., WelgeLussen U. and May C. A. 2005 Localization of collagen XVIII and endostatin in the human eye. Curr. Eye Res. 30, 27-34.
162. Ohno-Matsui K., Morita I., Tombran-Tink J., Mrazek D., Onodera M., Uetama T. et al. 2001 Novel mechanism for agerelated macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J. Cell Physiol. 189, 323-333.
163. Ohno-Matsui K., Yoshida T., Uetama T., Mochizuki M. and Morita I. 2003 Vascular endothelial growth factor upregulates pigment epitheliumderived factor expression via VEGFR1 in human retinal pigment epithelial cells. Biochem. Biophys. Res. Commun. 303, 962-967.
164. Oka C., Tsujimoto R., Kajikawa M., KoshibaTakeuchi K., Ina J., Yano M. et al. 2004 HtrA1 serine protease inhibits signaling mediated by Tgfbeta family proteins. Development131, 1041-1053.
165. O'Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Cao Y. et al. 1994a Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spr. Harb. Symp. Quant. Biol. 59, 471-482.
166. O'Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M. et al. 1994b Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell79, 315-328.
167. O'Reilly M. S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. S. et al. 1997 Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell88, 277-285.
168. O'Reilly M. S., Wiederschain D., StetlerStevenson W. G., Folkman J. and Moses M. A. 1999 Regulation of angiostatin production by matrix metalloproteinase2 in a model of concomitant resistance. J. Biol. Chem. 274, 29568-295671.
169. Ortego J., Escribano J., Becerra S. P. and CocaPrados M. 1996 Gene expression of the neurotrophic pigment epitheliumderived factor in the human ciliary epithelium. Synthesis and secretion into the aqueous humor. Invest. Ophthalmol. Vis. Sci. 37, 2759-2767.
170. Papapetropoulos A., Garcia-Cardena G., Madri J. A. and Sessa W. C. 1997 Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 100, 3131-3139.
171. Park K. W., Morrison C. M., Sorensen L. K., Jones C. A., Rao Y., Chien C. B. et al. 2003 Robo4 is a vascularspecific receptor that inhibits endothelial migration. Dev. Biol. 261, 251-267.
172. Patel J. I., Hykin P. G., Gregor Z. J., Boulton M. and Cree I. A. 2005 Angiopoietin concentrations in diabetic retinopathy. Br. J. Ophthalmol. 89, 480-483.
173. Patel M. and Chan C. C. 2008 Immunopathological aspects of agerelated macular degeneration. Semin Immunopathol 30, 97-110.
174. Patel J. I., TombranTink J., Hykin P. G., Gregor Z. J. and Cree I. A. 2006 Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. Exp. Eye Res. 82, 798-806.
175. Patel S., Rowe M. J., Winters S. A. and Ohls R. K. 2008 Elevated erythropoietin mRNA and protein concentrations in the developing human eye. Pediatr. Res. 63, 394-397.
176. Paulus Y. M. and Gariano R. F. 2009 Diabetic retinopathy: a growing concern in an aging population. Geriatrics64, 16-20.
177. Pelikanova T. 2007 Pathogenesis of diabetic retinopathy. Vnitr. Lek. 53, 498-505.
178. Penfold P. L., Provis J. M. and Billson F. A. 1987 Agerelated macular degeneration: ultrastructural studies of the relationship of leucocytes to angiogenesis. Graefes Arch. Clin. Exp. Ophthalmol. 225, 70-76.
179. Penn J. S., Madan A., Caldwell R. B., Bartoli M., Caldwell R. W. and Hartnett M. E. 2008 Vascular endothelial growth factor in eye disease. Prog. Retin Eye Res. 27, 331-371.
180. Peters K. G. 1998 Vascular endothelial growth factor and the angiopoietins: working together to build a better blood vessel. Circ. Res. 83, 342-343.
181. Pierce E. A., Avery R. L., Foley E. D., Aiello L. P. and Smith L. E. 1995 Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. USA92, 905-909.
182. Pierce E. A., Foley E. D. and Smith L. E. 1996 Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch. Ophthalmol. 114, 1219-1228.
183. Plantner J. J., Jiang C. Smine A. 1998 Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration. Exp. Eye Res. 67, 637-645.
184. Poulaki V., Joussen A. M., Mitsiades N., Mitsiades C. S., Iliaki E. F. and Adamis A. P. 2004 Insulinlike growth factorI plays a pathogenetic role in diabetic retinopathy. Am. J. Pathol. 165, 457-469.
185. Presta M., Tiberio L., Rusnati M., Dell'Era P. and Ragnotti G. 1991 Basic fibroblast growth factor requires a longlasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells. Cell Regul. 2, 719-726.
186. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R. and Rusnati M. 2005 Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16, 159-178.
187. Presta M., Andres G., Leali D., Dell'era P. and Ronca R. 2009 In-flammatory cells and chemokines sustain FGF2induced angiogenesis. Eur. Cytokine Netw. 20, 39-50.
188. Prosser B. E., Johnson S., Roversi P., Herbert A. P., Blaum B. S., Tyrrell J. et al. 2007 Structural basis for complement factor H linked agerelated macular degeneration. J. Exp. Med. 204, 2277-2283.
189. Ray D., Mishra M., Ralph S., Read I., Davies R. and Brenchley P. 2004 Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes53, 861-864.
190. Renno R. Z., Youssri A. I., Michaud N., Gragoudas E. S. and Miller J. W. 2002 Expression of pigment epitheliumderived factor in experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 43, 1574-1580.
191. Roberts W. G. and Palade G. E. 1995 Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. 108, 2369-2379.
192. Rosenthal R., Malek G., Salomon N., PeillMeininghaus M., Coeppicus L., Wohlleben H. et al. 2005 The fibroblast growth factor receptors, FGFR1 and FGFR2, mediate two independent signalling pathways in human retinal pigment epithelial cells. Biochem. Biophys. Res. Commun. 337, 241-247.
193. Ross R. J., Bojanowski C. M., Wang J. J., Chew E. Y., Rochtchina E., Ferris F. L. 3rd et al. 2007 The LOC387715 polymorphism and agerelated macular degeneration: replication in three casecontrol samples. Invest. Ophthalmol. Vis. Sci. 48, 1128-1132.
194. Rousseau B., Dubayle D., Sennlaub F., Jeanny J. C., Costet P., Bikfalvi A. et al. 2000 Neural and angiogenic defects in eyes of transgenic mice expressing a dominantnegative FGF receptor in the pigmented cells. Exp. Eye Res. 71, 395-404.
195. Ruberte J., Ayuso E., Navarro M., Carretero A., Nacher V., Haurigot V. et al. 2004 Increased ocular levels of IGF1 in transgenic mice lead to diabeteslike eye disease. J. Clin. Invest. 113, 1149-1157.
196. Sack R. A., Beaton A. R. and Sathe S. 1999 Diurnal variations in angiostatin in human tear fluid: a possible role in prevention of corneal neovascularization. Curr. Eye Res. 18, 186-193.
197. Saishin Y., Silva R. L., Kachi S., Aslam S., Gong Y. Y., Lai H. et al. 2005 Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. Hum. Gene. Ther. 16, 473-478.
198. Sakurai E., Anand A., Ambati B. K., van Rooijen N. and Ambati J. 2003a Macrophage depletion inhibits experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44, 3578-3585.
199. Sakurai E., Taguchi H., Anand A., Ambati B. K., Gragoudas E. S., Miller J. W. et al. 2003b Targeted disruption of the CD18 or ICAM1 gene inhibits choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44, 2743-2749.
200. Sakurai Y., Ohgimoto K., Kataoka Y., Yoshida N. and Shibuya M. 2005 Essential role of Flk1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc. Natl. Acad. Sci. USA102, 1076-1081.
201. Sall J. W., Klisovic D. D., O'Dorisio M. S. and Katz S. E. 2004 Somatostatin inhibits IGF1 mediated induction of VEGF in human retinal pigment epithelial cells. Exp. Eye Res. 79, 465-476.
202. Sarlos S., Rizkalla B., Moravski C. J., Cao Z., Cooper M. E. and WilkinsonBerka J. L. 2003 Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am. J. Pathol. 163, 879-887.
203. Sato T., Kusaka S., Shimojo H. and Fujikado T. 2009 Vitreous Levels of Erythropoietin and Vascular Endothelial Growth Factor in Eyes with Retinopathy of Prematurity. Ophthalmology116, 1599-1603.
204. Schneider J. K., Gardner D. K. and Cordero L. 2008 Use of recombinant human erythropoietin and risk of severe retinopathy in extremely lowbirthweight infants. Pharmacotherapy28, 1335-1340.
205. Schwesinger C., Yee C., Rohan R. M., Joussen A. M., Fernandez A., Meyer T. N. et al. 2001 Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am. J. Pathol. 158, 1161-1172.
206. Sears J. E., Hoppe G., Ebrahem Q. and AnandApte B. 2008 Prolyl hydroxylase inhibition during hyperoxia prevents oxygeninduced retinopathy. Proc. Natl. Acad. Sci. USA105, 19898-19903.
207. Seddon J. M., Gensler G., Milton R. C., Klein M. L. and Rifai N. 2004 Association between Creactive protein and agerelated macular degeneration. JAMA291, 704-710.
208. Sepp N. T., Li L. J., Lee K. H., Brown E. J., Caughman S. W., Lawley T. J. et al. 1994 Basic fibroblast growth factor increasesexpression of the alpha v beta 3 integrin complex on human microvascular endothelial cells. J. Invest. Dermatol. 103, 295-299.
209. She H., Nakazawa T., Matsubara A., Hisatomi T., Young T. A., Michaud N. et al. 2007 Reduced photoreceptor damage after photodynamic therapy through blockade of nitric oxide synthase in a model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 48, 2268-2277.
210. Shi X. H., He S. Z. and Zhao S. H. 2004 Expression and signification of pigment epitheliumderived factor in experimental choroidal neovascularization of rat. Zhonghua Yan Ke Za Zhi40, 404-408.
211. Shibuya M. and ClaessonWelsh L. 2006 Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 312, 549-560.
212. Shih S. C., Ju M., Liu N. and Smith L. E. 2003 Selective stimulation of VEGFR1 prevents oxygeninduced retinal vascular degeneration in retinopathy of prematurity. J. Clin. Invest. 112, 50-57.
213. Shing Y., Folkman J., Sullivan R., Butterfield C., Murray J. and Klagsbrun M. 1984 Heparin affinity: purification of a tumorderived capillary endothelial cell growth factor. Science223, 1296-1299.
214. Shing Y., Folkman J., Haudenschild C., Lund D., Crum R. and Klagsbrun M. 1985 Angiogenesis is stimulated by a tumorderived endothelial cell growth factor. J. Cell Biochem. 29, 275-287.
215. Shono T., Kanetake H. and Kanda S. 2001 The role of mitogenactivated protein kinase activation within focal adhesions in chemotaxis toward FGF2 by murine brain capillary endothelial cells. Exp. Cell Res. 264, 275-283.
216. Shweiki D., Itin A., Soffer D. and Keshet E. 1992 Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature359, 843-845.
217. Silva K. C., Pinto C. C., Biswas S. K., de Faria J. B. and de Faria J. M. 2007 Hypertension increases retinal inflammation in experimental diabetes: a possible mechanism for aggravation of diabetic retinopathy by hypertension. Curr. Eye Res. 32, 533-541.
218. Simo R., Carrasco E., Garcia-Ramirez M. and Hernandez C. 2006 Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr. Diabetes Rev. 2, 71-98.
219. Singh N., Amin S., Richter E., Rashid S., Scoglietti V., Jani P. D. et al. 2005a Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest. Ophthalmol. Vis. Sci. 46, 1647-1652.
220. Singh N., Macnamara E., Rashid S., Ambati J., Kontos C. D., Higgins E. et al. 2005b Systemic soluble Tie2 expression inhibits and regresses corneal neovascularization. Biochem. Biophys. Res. Commun. 332, 194-199.
221. Singh N., Jani P. D., Suthar T., Amin S. and Ambati B. K. 2006 Flt-1 intraceptor induces the unfolded protein response, apoptotic factors, and regression of murine injury induced corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 47, 4787-4793.
222. Singh N., Higgins E., Amin S., Jani P., Richter E., Patel A. et al. 2007 Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization. Cornea26, 65-72.
223. Skopinski P., Rogala E., Duda-Krol B., Lipinska A., Sommer E., Chorostowska-Wynimko J. et al. 2005 Increased interleukin-18 content and angiogenic activity of sera from diabetic (Type 2) patients with background retinopathy. J. Diabet. Complications19, 335-338.
224. Smith L. E. 2005 IGF-1 and retinopathy of prematurity in the preterm infant. Biol. Neonate88, 237-244.
225. Smith L. E. 2008 Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest. Ophthalmol. Vis. Sci. 49, 5177-5182.
226. Smith L. E., Kopchick J. J., Chen W., Knapp J., Kinose F., Daley D. et al. 1997 Essential role of growth hormone in ischemia-induced retinal neovascularization. Science276, 1706-1709.
227. Smith L. E., Shen W., Perruzzi C., Soker S., Kinose F., Xu X. et al. 1999 Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat. Med. 5, 1390-1395.
228. Soubrane G., Jerdan J., Karpouzas I., Fayein N. A., Glaser B., Coscas G. et al. 1990 Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea. Invest. Ophthalmol. Vis. Sci. 31, 323-333.
229. Soubrane G., Cohen S. Y., Delayre T., Tassin J., Hartmann M. P., Coscas G. J. et al. 1994 Basic fibroblast growth factor experimentally induced choroidal angiogenesis in the minipig. Curr. Eye Res. 13, 183-195.
230. Spencer K. L., Hauser M. A., Olson L. M., Schmidt S., Scott W. K., Gallins P. et al. 2007 Protective effect of complement factor B and complement component 2 variants in agerelated macular degeneration. Hum. Mol. Genet. 16, 1986-1992.
231. Stokes C. L., Rupnick M. A., Williams S. K. and Lauffenburger D. A. 1990 Chemotaxis of human microvessel endothelial cells in response to acidic fibroblast growth factor. Lab. Invest. 63, 657-668.
232. Suchting S., Heal P., Tahtis K., Stewart L. M. and Bicknell R. 2005 Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration. FASEB J. 19, 121-123.
233. Suganthalakshmi B., Anand R., Kim R., Mahalakshmi R., Karthikprakash S., Namperumalsamy P. et al. 2006 Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol. Vis. 12, 336-341.
234. Sugihara T., Wadhwa R., Kaul S. C. and Mitsui Y. 1998 A novel alternatively spliced form of murine vascular endothelial growth factor, VEGF 115. J. Biol. Chem. 273, 3033-3038.
235. Suk K. K., Dunbar J. A., Liu A., Daher N. S., Leng C. K., Leng J. K. et al. 2008 Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model. J. AAPOS12, 233-238.
236. Suri C., Jones P. F., Patan S., Bartunkova S., Maisonpierre P. C., Davis S. et al. 1996 Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell87, 1171-1180.
237. Suri C., McClain J., Thurston G., McDonald D. M., Zhou H., Oldmixon E. H. et al. 1998 Increased vascularization in mice overexpressing angiopoietin-1. Science282, 468-471.
238. Suzuma K., Takagi H., Otani A., Oh H. and Honda Y. 1999 Expression of thrombospondin-1 in ischemia-induced retinal neovascularization. Am. J. Pathol. 154, 343-354.
239. Swaroop A., Branham K. E., Chen W. and Abecasis G. 2007 Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. Hum. Mol. Genet. 16, R174-R182.
240. Takagi H., Watanabe D., Suzuma K., Kurimoto M., Suzuma I., Ohashi H. et al. 2007 Novel role of erythropoietin in proliferative diabetic retinopathy. Diabetes Res. Clin. Pract. 77, S62-S64.
241. Takahashi H. and Shibuya M. 2005 The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. 109, 227-241.
242. Tang N. P., Zhou B., Wang B. and Yu R. B. 2009 HTRA1 promoter polymorphism and risk of age-related macular degeneration: a meta-analysis. Ann. Epidemiol. 19, 740-745.
243. Tawfik A., Sanders T., Kahook K., Akeel S., Elmarakby A. and Al-Shabrawey M. 2009 Suppression of retinal peroxisome proliferator-activated receptor gamma in experimental diabetes and oxygen-induced retinopathy: role of NADPH oxidase. Invest. Ophthalmol. Vis. Sci. 50, 878-884.
244. Teng Y., Cui H., Yang M., Song H., Zhang Q., Su Y. et al. 2009 Protective effect of puerarin on diabetic retinopathy in rats. Mol. Biol. Rep. 36, 1129-1133.
245. Terry T. L. 1942 Fibroblastic overgrowth of persistent Tunica Vasculosa Lentis in infants born prematurely: II. Report of cases clinical aspects. Trans. Am. Ophthalmol. Soc. 40, 262-284.
246. Thakkinstian A., Han P., McEvoy M., Smith W., Hoh J., Magnusson K. et al. 2006 Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. Hum. Mol. Genet. 15, 2784-2790.
247. Tong J. P., Shen Y., Chan W. M., Lin S. C. and Peng Z. P. 2006 Vascular endothelial growth factor and pigment epithelium-derived factor in aqueous humor of patients with choroidal neovascularization. Zhejiang Da Xue Xue Bao Yi Xue Ban35, 311-314.
248. Triebel J., Huefner M. and Ramadori G. 2009 Investigation of prolactin-related vasoinhibin in sera from patients with diabetic retinopathy. Eur. J. Endocrinol. 161, 345-353.
249. Tsutsumi C., Sonoda K. H., Egashira K., Qiao H., Hisatomi T., Nakao S. et al. 2003 The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J. Leukoc. Biol. 74, 25-32.
250. Tuo J., Smith B. C., Bojanowski C. M., Meleth A. D., Gery I., Csaky K. G. et al. 2004 The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. FASEB J. 18, 1297-1299.
251. Twining S. S., Wilson P. M. and Ngamkitidechakul C. 1999 Extrahepatic synthesis of plasminogen in the human cornea is upregulated by interleukins-1alpha and - 1beta. Biochem. J. 339, 705-712.
252. Uhlmann S., Friedrichs U., Eichler W., Hoffmann S. and Wiedemann P. 2001 Direct measurement of VEGF-induced nitric oxide production by choroidal endothelial cells. Microvasc. Res. 62, 179-189.
253. Underwood P. A., Bean P. A. and Gamble J. R. 2002 Rate of endothelial expansion is controlled by cell: cell adhesion. Int. J. Biochem. Cell. Biol. 34, 55-69.
254. Uthra S., Raman R., Mukesh B. N., Rajkumar S. A., Kumari R. P., Agarwal S. et al. 2007 Diabetic retinopathy and IGF-1 gene polymorphic cytosineadenine repeats in a Southern Indian cohort. Ophthalmic. Res. 39, 294-299.
255. Uthra S., Raman R., Mukesh B. N., Rajkumar S. A., Padmaja K. R., Paul P. G. et al. 2008 Association of VEGF gene polymorphisms with diabetic retinopathy in a south Indian cohort. Ophthalmic Genet. 29, 11-15.
256. Vanhaesebrouck S., Daniels H., Moons, L., Vanhole C., Carmeliet P. and De Zegher F. 2009 Oxygen-induced retinopathy in mice: amplification by neonatal IGF-I deficit and attenuation by IGF-I administration. Pediatr. Res. 65, 307-310.
257. Villegas-Becerril E., Gonzalez-Fernandez R., Perula-Torres L. and Gallardo-Galera J. M. 2006 IGF-I, VEGF and bFGF as predictive factors for the onset of retinopathy of prematurity (ROP). Arch. Soc. Esp. Oftalmol. 81, 641-646.
258. Wakabayashi Y., Usui Y., Okunuki Y., Takeuchi M., Kezuka T., Iwasaki T. et al. 2008 Increased levels of monokine induced by interferon-gamma (Mig) in the vitreous of patients with diabetic retinopathy. Diabetic Med. 25, 875-877.
259. Wang F. H., Sun X. D., Zhang X., Xu X., Zhu Q., Huang J. N. et al. 2007 Role of pigment epithelium-derived factor on proliferation and migration of choroidal capillary endothelium induced by vascular endothelial growth factor in vitro. Chin. Med. J. 120, 1534-1538.
260. Wang Z. Y., Shen L. J., Tu L., Hu D. N., Liu G. Y., Zhou Z. L. et al. 2009 Erythropoietin protects retinal pigment epithelial cells from oxidative damage. Free Radic. Biol. Med. 46, 1032-1041.
261. Watanabe D. 2007 Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. Nippon Ganka Gakkai Zasshi111, 892-898.
262. Watanabe D., Suzuma K., Matsui S., Kurimoto M., Kiryu J., Kita M. et al. 2005a Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N. Engl. J. Med. 353, 782-792.
263. Watanabe D., Suzuma K., Suzuma I., Ohashi H., Ojima T., Kurimoto M. et al. 2005b Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 139, 476-481.
264. Watanabe D., Takagi H., Suzuma K., Oh H., Ohashi H. and Honda Y. et al. 2005c Expression of connective tissue growth factor and its potential role in choroidal neovascularization. Retina25, 911-918.
265. Werdich X. Q., McCollum G. W., Rajaratnam V. S. and Penn J. S. 2004 Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygeninduced retinopathy. Exp. Eye Res. 79, 623-630.
266. Wilkinson-Berka J. L. 2004 Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr. Pharm. Des. 10, 3331-3348.
267. Wilkinson-Berka J. L. 2006 Angiotensin and diabetic retinopathy. Int. J. Biochem. Cell Biol. 38, 752-765.
268. Wilkinson-Berka J. L. and Fletcher E. L. 2004 Angiotensin and bradykinin: targets for the treatment of vascular and neuro-glial pathology in diabetic retinopathy. Curr. Pharm. Des. 10, 3313-3330.
269. Wilkinson-Berka J. L., Babic S., De Gooyer T., Stitt A. W., Jaworski K., Ong L. G. et al. 2004 Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Am. J. Pathol. 164, 1263-1273.
270. Wilkinson-Berka J. L., Jones D., Taylor G., Jaworski K., Kelly D. J., Ludbrook S. B. et al. 2006 SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 47, 1600-1605.
271. Witzenbichler B., Maisonpierre P. C., Jones P., Yancopoulos G. D. and Isner J. M. 1998 Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J. Biol. Chem. 273, 18514-18521.
272. Woessner Jr J. F. 1994 The family of matrix metalloproteinases. Ann. N. Y. Acad. Sci. 732, 11-21.
273. Wu W. C., Kao Y. H., Hu P. S. and Chen J. H. 2007 Geldanamycin, a HSP90 inhibitor, attenuates the hypoxia-induced vascular endothelial growth factor expression in retinal pigment epithelium cells in vitro. Exp. Eye Res. 85, 721-731.
274. Xie B., Shen J., Dong A., Swaim M., Hackett S. F., Wyder L. et al. 2008 An Adam 15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization. FASEB J. 22, 2775-2783.
275. Yamagishi S., Nakamura K. and Imaizumi T. 2005 Advanced glycation end products (AGEs) and diabetic vascular complications. Curr. Diabetes Rev. 1, 93-106.
276. Yamagishi S., Matsui T., Nakamura K., Inoue H., Takeuchi M., Ueda S. et al. 2008 Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc. Res. 75, 130-134.
277. Yancopoulos G. D., Davis S., Gale N. W., Rudge J. S., Wiegand S. J. and Holash 2000 et al. 2000 Vascular-specific growth factors and blood vessel formation. Nature407, 242-248.
278. Yang Z., Stratton C., Francis P. J., Kleinman M. E., Tan P. L, Gibbs D. et al. 2008 Toll-like receptor 3 and geographic atrophy in agerelated macular degeneration. N. Engl. J. Med. 359, 1456-1463.
279. Yates J. R., Sepp T., Matharu B. K., Khan J. C., Thurlby D. A., Shahid H. et al. 2007 Complement C3 variant and the risk of agerelated macular degeneration. N. Engl. J. Med. 357, 553-561.
280. Yaylali V., Ohta T., Kaufman S. C., Maitchouk D. Y. and Beuerman R. W. 1998 In vivo confocal imaging of corneal neovascularization. Cornea17, 646-653.
281. Ye H. Q. and Azar D. T. 1998 Expression of gelatinases A and B, and TIMPs 1 and 2 during corneal wound healing. Invest. Ophthalmol. Vis. Sci. 39, 913-921.
282. Ye H. Q., Maeda M., Yu F. S. and Azar D. T. 2000 Differential expression of MT1-MMP (MMP-14) and collagenase III (MMP-13) genes in normal and wounded rat corneas. Invest. Ophthalmol. Vis. Sci. 41, 2894-2899.
283. Yokoi M., Yamagishi S., Saito A., Yoshida Y., Matsui T., Saito W. et al. 2007 Positive association of pigment epithelium-derived factor with total antioxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy. Br. J. Ophthalmol. 91, 885-887.
284. Zhou J., Pham L., Zhang N., He S., Gamulescu M. A., Spee C. et al. 2005 Neutrophils promote experimental choroidal neovascularization. Mol. Vis. 11, 414-424.
285. Zubilewicz A., Hecquet C., Jeanny J. C., Soubrane G., Courtois Y. and Mascarelli 2001 Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: a comparative study with VEGF. Oncogene20, 1403-1413.